RT Journal Article
SR Electronic
T1 Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.03.20205278
DO 10.1101/2020.10.03.20205278
A1 Ku, Chee Wai
A1 Shivani, Durai
A1 Kwan, Jacqueline Q T
A1 Loy, See Ling
A1 Erwin, Christina
A1 Ko, Karrie K K
A1 Ng, Xiang Wen
A1 Oon, Lynette
A1 Thoon, Koh Cheng
A1 Kalimuddin, Shirin
A1 Chan, Jerry KY
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.03.20205278.abstract
AB Background Effective management of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) requires large-scale testing. Collection of nasopharyngeal swab (NPS) by healthcare workers (HCW) is currently used to diagnose SARS-CoV-2, which increases the risk of transmission to HCWs. Self-administered saliva and buccal swabs are convenient, painless and safe alternative sample collection methods.Methods A cross-sectional single centre study was conducted on 42 participants who were tested positive for SARS-CoV-2 via NPS within the past 7 days. A self-collected saliva and buccal swab and a HCW-collected NPS were obtained. Real-time polymerase chain reaction (RT-PCR) was performed and cycle threshold (CT) values were obtained. Positive percent agreement (PPA), negative percent agreement (NPA) and overall agreement (OA) were calculated for saliva and buccal swabs, as compared with NPS.Results Among the 42 participants, 73.8% (31/42) tested positive via any one of the 3 tests. With reference to NPS, the saliva test had PPA 66.7%, NPA 91.7% and OA 69.0%. The buccal swab had PPA 56.7%, NPA 100% and OA 73.8%. Presence of symptoms improved diagnostic accuracy. There was no statistically significant association between CT values and duration of symptom onset within the first 12 days of symptoms for all three modalities.Conclusion Self-collected saliva tests and buccal swabs have only moderate agreement with HCW-collected NPS swabs. Primary screening for SARS-CoV-2 may be performed with a saliva test or buccal swab, with a negative test warranting a confirmatory NPS to avoid false negatives. This combined strategy minimizes discomfort and reduces the risk of spread to the community and HCWs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the FY2020 SingHealth Duke-NUS Obstetrics & Gynaecology Academic Clinical Programme, SingHealth Duke-NUS COVID-19 Innovation Grant [01/FY2020/P2(C1)/01-A48]. JCKY received support from Singapore Ministry of Health National Medical Research Council CSA-SI-0008-2016.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Singhealth (CIRB Ref No 2020/2655)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author JCKY. The data are not publicly available due to them containing information that could compromise research participant privacy/consent.